Literature DB >> 10935425

Recognition, treatment and complications of meningococcal disease.

F A Riordan1, A P Thomson.   

Abstract

Meningococcal disease remains a major cause of death in young children. A decrease in mortality requires recognition and treatment of the disease at a number of stages in the illness. Life-threatening meningococcal disease usually presents as septicaemia rather than meningitis. The cardinal feature of meningococcal septicaemia is the purpuric rash. Many parents recognise the rash and seek medical advice because of it. When primary care physicians recognise the rash, the administration of parenteral penicillin may decrease mortality. However, antibacterials are not given promptly if there is no rash or if the disease presents in an atypical form. In hospital, antibacterial therapy with a third-generation cephalosporin should be given. Disease severity needs to be assessed by a valid method, such as the Glasgow Meningococcal Septicaemia Prognostic Score (GMSPS). This can identify those patients who need intensive care and/or might benefit from new therapies. The 2 life-threatening complications are septic shock and meningoencephalitis with raised intracranial pressure. Despite numerous case reports of success with potential new treatments, none has been proven safe and/or effective by controlled trials. Although it is tempting to focus on new treatments, the early recognition of severe meningococcal disease by parents, primary care physicians and junior hospital doctors is equally, if not more, important as a potential means of decreasing mortality.

Entities:  

Mesh:

Year:  1999        PMID: 10935425     DOI: 10.2165/00128072-199901040-00003

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  146 in total

1.  Early treatment of meningococcal disease.

Authors:  H T Sørensen; J Møller-Petersen; H B Krarup; H Pedersen; H Hansen; H Hamburger
Journal:  BMJ       Date:  1992-09-26

Review 2.  Should we use dexamethasone in meningitis? The Meningitis Working Party of the British Paediatric Immunology and Infectious Diseases Group.

Authors: 
Journal:  Arch Dis Child       Date:  1992-11       Impact factor: 3.791

3.  Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease.

Authors:  P Brandtzaeg; G B Joø; B Brusletto; P Kierulf
Journal:  Thromb Res       Date:  1990-01-15       Impact factor: 3.944

4.  Thrombocytopenia and bleeding complications in severe cases of meningococcal infection treated with heparin, dextran 70 and chlorpromazine.

Authors:  P M Niklasson; M Blombäck; P Lundbergh; T Strandell
Journal:  Scand J Infect Dis       Date:  1972

5.  Prospective study of the treatment of septic shock.

Authors:  I M Ledingham; C S McArdle
Journal:  Lancet       Date:  1978-06-03       Impact factor: 79.321

6.  Emergency management of meningococcal disease.

Authors:  A J Pollard; J Britto; S Nadel; C DeMunter; P Habibi; M Levin
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

Review 7.  Antibiotic resistance in Neisseria meningitidis.

Authors:  B A Oppenheim
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

8.  Sequelae one year after meningococcal disease.

Authors:  A Naess; A Halstensen; H Nyland; S H Pedersen; P Møller; R Borgmann; J L Larsen; E Haga
Journal:  Acta Neurol Scand       Date:  1994-02       Impact factor: 3.209

Review 9.  Meningococcal disease: still with us.

Authors:  H Peltola
Journal:  Rev Infect Dis       Date:  1983 Jan-Feb

10.  Dexamethasone therapy for children with bacterial meningitis. Meningitis Study Group.

Authors:  E R Wald; S L Kaplan; E O Mason; D Sabo; L Ross; M Arditi; B L Wiedermann; W Barson; K S Kim; R Yogov
Journal:  Pediatrics       Date:  1995-01       Impact factor: 7.124

View more
  3 in total

1.  Point-of-care diagnostic technology in paediatric ambulatory care: a qualitative interview study of English clinicians and stakeholders.

Authors:  Meriel Elizabeth Raymond; Chris Bird; Oliver van Hecke; Margaret Glogowska; Gail Hayward
Journal:  BMJ Open       Date:  2022-06-07       Impact factor: 3.006

2.  Signs and symptoms in children with a serious infection: a qualitative study.

Authors:  Ann Van den Bruel; Rudi Bruyninckx; Etienne Vermeire; Peter Aerssens; Bert Aertgeerts; Frank Buntinx
Journal:  BMC Fam Pract       Date:  2005-08-26       Impact factor: 2.497

3.  Serious infections in children: an incidence study in family practice.

Authors:  Ann Van den Bruel; Stefaan Bartholomeeusen; Bert Aertgeerts; Carla Truyers; Frank Buntinx
Journal:  BMC Fam Pract       Date:  2006-03-28       Impact factor: 2.497

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.